peppersite
Bioregulatororal

Cartalax

Cartalax is an oral peptide bioregulator, discussed under the short sequence AED (alanyl-glutamyl-aspartic acid), that is referenced for connective tissue and cartilage support. It has been studied in cell cultures, and its mechanism is proposed, not clinically established.

Researched for
Recovery

At a glance

Type
Bioregulator
Given by
oral
Evidence
Not yet audited here; the reference library calls it theoretical
Reported amount
None on file.

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

The reference does not report a single injectable amount for Cartalax, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.

Not yet audited

We have not published an audit on Cartalax. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

Cartalax is thought to act by changing how cartilage cells behave and which genes they switch on, though this is a proposal and not a proven drug-receptor model. In one 2023 study, the short peptide AED increased the number of cartilage cells (chondrocytes) in cultures from young and old rats. Researchers link the idea to gene expression, protein synthesis and upkeep of the extracellular matrix, the scaffold around cells. These are cell-culture findings and do not show that Cartalax rebuilds human cartilage or reduces pain.

In technical termsTissue-specific peptide bioregulation (theoretical).

Reported side effects

Not ruled out: no Cartalax-specific side-effect data has been published and there is no FDA-approved label, and the source notes that a lack of reports is not proof of safety. It lists immune reactions, impurities, contamination, inconsistent potency and unknown risks as general concerns for unapproved or poorly characterized peptides. These are general concerns, not rates measured for Cartalax.

Who should avoid it

People who are pregnant or breastfeeding: safety is not established for unapproved peptides.

People with active cancer: safety is not established.

People with autoimmune disease or who are immunosuppressed: safety is not established.

People with significant kidney or liver disease: safety is not established.

People with planned surgery or chronic infection: safety is not established.

People on complex medication regimens: drug-interaction data are incomplete, because the clinical studies and safety monitoring that normally map interactions do not exist for Cartalax.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things